Vizient Hosts 2025 Cell, Gene & Specialty Pharmacy Symposium to Advance Patient Care and Health System Readiness
IRVING, Texas--(BUSINESS WIRE)-- Vizient hosted its second annual cell, gene and specialty pharmacy symposium, bringing together thought leaders committed to the advancement of health-system pharmacy in the management, delivery, and optimization of advanced therapeutics. The event was held April 22-24 in Frisco, Texas.
'The growth of cell and gene therapies is accelerating change across healthcare, requiring new approaches to forecasting, resource planning, and patient access to ensure readiness for what's ahead,' said Carina Dolan, PharmD, MS, BCOP, associate vice president, market insights and forecasting, Pharmacy Solutions, Vizient.
As this growing class of cell and gene therapeutics reshapes care delivery, site-of-care strategies, and health system economics, industry stakeholders are seeking how to manage these new and promising drugs. Attendees exchanged ideas, operational and financial challenges and hope for the advancement of patient care.
'Cell and gene therapies are transforming care for patients with complex conditions. To deliver on their promise, we must evolve how we provide care—expanding access, building infrastructure, and preparing teams for a new era of treatment,' said Tami John, MD, Stanford Children's Health, who delivered the keynote address.
Rhae Ana Gamber, associate principle, intelligence at Sg2, a Vizient company, presented with colleagues, 'Exploring Today's Market Trends for High Impact Disease,' which projected that with adoption of emerging cell and gene therapies, healthcare organizations could see a decline in utilization across several service lines. For example, cell and gene therapy for benign hematology, including sickle cell, could reduce current annual inpatient discharges by 29% by 2034 from a 2024 baseline of roughly 44,000.
Vizient also provided an overview for new therapies currently in the approval process. Amanda Frick, sr. clinical manager, pharmacy market insights and forecasting noted that in addition to 25 FDA-approved gene and cellular immunotherapies on the market today, Vizient is monitoring 265 gene and cellular immunotherapy products in the U.S. pharmacy pipeline. Jenna Stern, vice president, regulatory affairs and public policy highlighted how major policy shifts are reshaping the regulatory landscape. These factors underscore the urgency for healthcare organizations to develop procedures for how to manage these costly therapeutics, which can range up to over $1 million per dose.
Across multiple panel discussions, panelists emphasized the critical role of negotiating comprehensive contracts to safeguard against unexpected challenges. Additional key takeaways included insights from the payer perspective, strategies to improve patient access and advocacy, the importance of streamlining interdepartmental approvals, and efforts to bridge the gap between pharmacy and finance.
Learn more about how Vizient helps providers find cell and gene therapy solutions.
Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
RFK Jr. will ‘end the war' against alternative medicine at the FDA, from stem cell therapy to chelation. Here's what to know
Health and Human Services Secretary Robert F. Kennedy, Jr. doubled down on his support for non-pharmaceutical health treatments during a recent podcast appearance, saying, 'We're going to end the war at the FDA against alternative medicine.' Speaking on the Ultimate Human podcast with host Gary Brecka, a 'renowned Human Biologist, biohacker, and longevity expert,' according to the website, Kennedy said he would fix the U.S. Food and Drug Administration's bias against the following: stem cell treatments, chelating drugs, vitamins and minerals, amino acids, peptides, and hyperbaric chambers. 'Our position is that the FDA has a job: Just do the science on these kinds of issues and then tell the public what they've learned from the science … but don't tell physicians what they can and cannot prescribe,' he said. And as far as the patients go, he said, 'If you want to take an experimental drug … you ought to be able to do that.' RFK Jr. added, 'We don't want to have the Wild West. We want to make sure that information is out there. But we also want to respect the intelligence of the American people' to decide what treatments will benefit them the most. He acknowledged that, with this approach, there will be 'charlatans' as well as 'people who have bad results' from various alternative treatments. 'But ultimately,' he said, 'you can't prevent that either way, and leaving the whole thing in the hands of pharma is not working for us.' Brecka called Kennedy's pronouncements 'music to my ears.' Below, what you need to know about the alternative therapies RFK Jr. is advocating for. What is it: It's a way to repair diseased or injured tissue in the body using stem cells—cells that can self-renew or become other types of tissues—typically grown in a lab, manipulated, and then be implanted into the patient. What it does: Though it's considered to be largely experimental, the FDA does permit stem cell therapies for blood and immune disorders. Leukemia, lymphoma, neuroblastoma, and multiple myeloma, for example, are also often treated this way, with bone marrow treatments, which are backed by decades of science. Other types of the treatment are still in clinical trials, while more and more wellness centers are offering the treatment for unapproved reasons, using cells drawn from the patient's body and injected back in without manipulation for everything from autism and ALS to Parkinson's and better skin, according to the New York Times. Kennedy told Brecka that he received the treatment for his voice disorder, spasmodic dysphonia, and that it helped him 'enormously,' but that he had to go to Antigua to access it. Risks: For starters, wellness clinic treatments cannot guarantee they are using actual stem cell, reported the Times. And improper injections can lead to a host of terrible consequences—clots, infections, blindness, and even the formation of tumors, which the FDA warned of in 2021. What it is: Chelation involves the use of certain chemicals to remove toxic heavy metals, such as mercury and lead, from the body; all FDA-approved chelation therapy products require a prescription and can only be used safely under the supervision of a healthcare practitioner. What it does: Some alternative medicine practitioners offer chelation therapy, through pill or injection, as a way to treat Alzheimer's, autism, diabetes, high blood pressure, or Parkinson's disease, all of which are unapproved and risky. Children's Health Defense, founded by Kennedy, has written about chelation as a way to treat autism, which compares 'autism with mercury poisoning' due to childhood vaccines that contained the preservative thimerosal (largely mercury) before it was removed in 2001. Some flu shots still contain the preservative, but, says the Centers for Disease Control and Prevention, 'There is no evidence of harm caused by the low doses of thimerosal in vaccines.' Risks: The FDA warns specifically about using chelation therapy for autism, and notes, 'Chelating important minerals needed by the body can lead to serious and life-threatening outcomes.' While minor risks may include fever, headache, muscle pain, and nausea or vomiting, severe reactions range from heart failure and kidney damage to respiratory failure and seizures, according to the Cleveland Clinic. What they are: Dietary supplements in almost every letter of the alphabet, from A to zinc, are over-the-counter pills or liquids that contain nutritional boosts of vitamins and minerals. What they aim to help: Vitamin and mineral supplements aim to fill in with necessary nutrients that a person is not getting through food—though nutritionists believe that healthy food is the best source of such vitamins and minerals. Studies have found supplements may help with practically any issue under the sun—energy, heart issues, cognitive function, gut health, sleep, and more. Risks: The U.S. Food and Drug Administration regulates supplements, but doesn't approve them for safety or effectiveness before they are sold to the public. Some may cause liver damage and toxicity, while others may just be a waste of money. What it is: Amino acids are often referred to as the 'building blocks of proteins,' needed for building proteins, hormones, and neurotransmitters. are compounds that play many critical roles in your body. You need them for vital processes such as building proteins, hormones, and neurotransmitters. Amino acids are concentrated in protein-rich foods such as meat, fish, and soybeans, and foods that contain all nine essential amino acids are called complete proteins. Peptides are short proteins, and come in the form of hormones such as follicle-stimulating hormone (FSH), and creatine and collagen. What they aim to help: Amino acid supplements may help with various issues—such as L-arginine for blood flow and inflammation; tryptophan for mood and sleep; and valine, leucine, and isoleucine to help with energy and athletic performance. Taking collagen supplements may help strengthen nails and bones, while people take creatine for boosting workouts and building muscle growth. Risks: Side effects of taking either can range from toxicity and gastrointestinal issues to effects on brain function muscle protein balance. Creatine may cause muscle cramps and digestive problems (and may not have many benefits), while tryptophan may cause dizziness, headache, or nausea. And again, as with all supplements, the U.S. Food and Drug Administration regulates them, but doesn't approve them for safety or effectiveness before they are sold to the public. What it is: Hyperbaric oxygen therapy in a medical-grade, FDA-approved chamber lets you breathe pure oxygen—as opposed to everyday air, which is just 21% oxygen mixed with nitrogen. Hyperbaric oxygen is also highly pressurized, thereby allowing the lungs to take more in. Home chambers (used by folks including Lebron James, LeAnn Rimes, and Mayim Bialik), as well as those offered in many wellness clinics, do not deliver 100% oxygen. Instead, they use regular air that is 30% more pressurized than normal for what's known as 'mild hyperbarics.' What it aims to help: The FDA has been regulating HBOT chambers since 1976, and has officially cleared 13 medical conditions—such as decompression sickness, burns, radiation injury, and certain wounds—for such treatment. But it's used off-label for many other reasons, including concussions, traumatic brain injury, long COVID, age reversal, stroke recovery, fibromyalgia, and improved brain function, many of which are being looked at in ongoing clinical trials. Risks: For medical-grade chambers, risks include ear and sinus pain, middle ear injuries, temporary vision changes, and lung collapse, which is rare, according to the FDA. For mild hyperbarics, risks include potential exposure to toxic oils from some compressors, carbon dioxide buildup that brings a risk of hypoxia inside the chamber—or, according to some experts and a body of inconclusive evidence, that the treatment may simply be ineffective. This story was originally featured on
Yahoo
37 minutes ago
- Yahoo
Oceaneering Announces CFO Succession Plan
HOUSTON, June 06, 2025--(BUSINESS WIRE)--Oceaneering International, Inc. (NYSE: OII) ("Oceaneering") today announced a Chief Financial Officer ("CFO") succession plan. Alan R. Curtis, Senior Vice President & CFO, has announced his decision to retire from his position effective January 1, 2026. Mr. Curtis began his career with Oceaneering in 1995 as a Financial Controller and has served in a variety of roles, including most recently as CFO since 2015. Addressing Mr. Curtis's pending retirement, President and Chief Executive Officer Rod Larson said, "On behalf of all Oceaneers, I would like to extend our deep gratitude to Alan for his financial leadership and strategic insights over the past decade. Under his leadership, we have consistently delivered steady shareholder returns and significantly enhanced our portfolio, enabling us to 'solve the unsolvable' for our customers in the most challenging environments. His extensive knowledge of Oceaneering and commitment to operational excellence and talent development have been instrumental to our success, and we wish him the best in his well-deserved retirement." M. Kevin McEvoy, Chairman of Oceaneering's Board of Directors, added, "Since I hired Alan 30 years ago, he has demonstrated integrity and a natural curiosity about Oceaneering's diverse services, products, and capabilities. Through his passion for the business, he developed close partnerships with our segment leaders, leading initiatives that strengthened our financial and organizational framework, and that continue to drive our financial and technological growth." Michael W. Sumruld will join Oceaneering as Senior Vice President of Finance on September 1, 2025, and is expected to later succeed Mr. Curtis as CFO upon Mr. Curtis's retirement from such position. Mr. Curtis will continue to serve Oceaneering in a supporting role to provide for an orderly transition of duties. Mr. Sumruld will report to Mr. Larson. Mr. Sumruld most recently served as Senior Vice President and CFO for Parker Drilling Company from October 2017 until its sale to Nabors Industries Ltd. in March 2025. In that role, he managed the company's investor relations, corporate development, treasury, finance and accounting, tax, financial planning and analysis, compliance, operations integrity, and information technology organizations. Prior to his time at Parker Drilling Company, Mr. Sumruld held positions at LyondellBasell Industries N.V. and at Baker Hughes Incorporated. He is a certified public accountant and holds a bachelor's degree in accounting from the University of Houston and a Master of Business Administration from Texas A&M University. Regarding Mr. Sumruld's appointment, Mr. Larson said, "We are pleased to welcome Mike following a thoughtful succession planning process. I know Mike quite well from our work together at Baker Hughes on the North American offshore business, where he proved himself to be a strong, people-focused leader with a collaborative, business-oriented approach. The Board is excited that Mike will be joining the management team to drive Oceaneering's continued growth and shareholder value." Oceaneering is a global technology company delivering engineered services and products and robotic solutions to the offshore energy, defense, aerospace, and manufacturing industries. For more information, please visit View source version on Contacts Hilary FrisbieSenior Director, Investor Relations713-329-4755investorrelations@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
41 minutes ago
- Business Wire
Oceaneering Announces CFO Succession Plan
HOUSTON--(BUSINESS WIRE)--Oceaneering International, Inc. (NYSE: OII) ('Oceaneering') today announced a Chief Financial Officer ('CFO') succession plan. Alan R. Curtis, Senior Vice President & CFO, has announced his decision to retire from his position effective January 1, 2026. Mr. Curtis began his career with Oceaneering in 1995 as a Financial Controller and has served in a variety of roles, including most recently as CFO since 2015. Addressing Mr. Curtis's pending retirement, President and Chief Executive Officer Rod Larson said, 'On behalf of all Oceaneers, I would like to extend our deep gratitude to Alan for his financial leadership and strategic insights over the past decade. Under his leadership, we have consistently delivered steady shareholder returns and significantly enhanced our portfolio, enabling us to 'solve the unsolvable' for our customers in the most challenging environments. His extensive knowledge of Oceaneering and commitment to operational excellence and talent development have been instrumental to our success, and we wish him the best in his well-deserved retirement.' M. Kevin McEvoy, Chairman of Oceaneering's Board of Directors, added, 'Since I hired Alan 30 years ago, he has demonstrated integrity and a natural curiosity about Oceaneering's diverse services, products, and capabilities. Through his passion for the business, he developed close partnerships with our segment leaders, leading initiatives that strengthened our financial and organizational framework, and that continue to drive our financial and technological growth.' Michael W. Sumruld will join Oceaneering as Senior Vice President of Finance on September 1, 2025, and is expected to later succeed Mr. Curtis as CFO upon Mr. Curtis's retirement from such position. Mr. Curtis will continue to serve Oceaneering in a supporting role to provide for an orderly transition of duties. Mr. Sumruld will report to Mr. Larson. Mr. Sumruld most recently served as Senior Vice President and CFO for Parker Drilling Company from October 2017 until its sale to Nabors Industries Ltd. in March 2025. In that role, he managed the company's investor relations, corporate development, treasury, finance and accounting, tax, financial planning and analysis, compliance, operations integrity, and information technology organizations. Prior to his time at Parker Drilling Company, Mr. Sumruld held positions at LyondellBasell Industries N.V. and at Baker Hughes Incorporated. He is a certified public accountant and holds a bachelor's degree in accounting from the University of Houston and a Master of Business Administration from Texas A&M University. Regarding Mr. Sumruld's appointment, Mr. Larson said, 'We are pleased to welcome Mike following a thoughtful succession planning process. I know Mike quite well from our work together at Baker Hughes on the North American offshore business, where he proved himself to be a strong, people-focused leader with a collaborative, business-oriented approach. The Board is excited that Mike will be joining the management team to drive Oceaneering's continued growth and shareholder value.' Oceaneering is a global technology company delivering engineered services and products and robotic solutions to the offshore energy, defense, aerospace, and manufacturing industries. For more information, please visit
